European Union´s Horizon 2020 – Lipum2020-06-23T06:45:31+02:00

OFFICAL PROJECT SITE 

Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

2108, 2019

Lipum presents at Biostock Live

augusti 21st, 2019|

On August 27, Lipums CEO Einar Pontén will present our recent progress towards a novel treatment of chronic inflammatory diseases. The presentation will be broadcasted live on the web from 10am. On this autumn's first BioStock Live Investor Event you have the chance to listen to presentations and talk with [...]

1408, 2019

Lipum invites to shareholders meeting

augusti 14th, 2019|

On August 28, Lipum shareholders will meet at Clarion Hotel Arlanda Airport. The recent progress and plans for the future will be presented and discussed. More detailed information will be sent out in personal mail. Warm welcome!

1406, 2019

Kallelse till årsstämma i Lipum AB

juni 14th, 2019|

Aktieägarna i Lipum AB, org. nr. 556813-5999 (“Lipum”), kallas härmed till årsstämma fredagen den 28 juni 2019, kl. 09:00 på Tvistevägen 48C i Umeå. […]

1705, 2019

Getting roasted by investors

maj 17th, 2019|

As a Horizon 2020 beneficiary we are invited to the SME Instrument Phase 2 Welcome Day organized by the European Innovation Council (EIC) Pilot in Brussels, May 22-23. Besides business networking the agenda includes: “Get roasted by investors – ready to go?”, “Success story from SME Instrument Innovator” and “Learn [...]

705, 2019

Pernilla Abrahamsson joins as Chief Operating Officer

maj 7th, 2019|

Press release may 7, 2019 ”Lipum is a very interesting company in an exciting development. Soon in the clinical phase and I am looking forward to all challenges ahead of us”, says Pernilla Abrahamsson. […]

Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€

Start:
2018-11-01

End:
2020-07-31

Till toppen